According to a post by the account @ChinaSelect on October 16, 2026, inspectors from the US Food and Drug Administration (FDA) found numerous extremely serious sanitary violations at two Chinese plants producing active pharmaceutical ingredients for combination GLP-1 drugs, including black mold on equipment and extensive insect activity on ceilings, raising concerns about the safety of US pharmaceutical companies' reliance on Chinese supply chains.
Evidence EVIDENCE
Sources 1 · Archived 0
SourceTypeReliabilityLink
@ChinaSelect
2026-10-15 20:39 · FDA inspectors found black mold on equipment, significant insect activity in ceilings, and other egregious conditions at two Chinese factories producing active ingredients for compounded GLP-1 drugs. …
Media
●●●●●
Context CONTEXT
Cause
Not recorded yet
This event
US FDA Finds Serious Sanitary Violations at Two Chinese GLP-1 API Plants
2026.10.16 · Developing
Effect
Not recorded yet